Summary
Most claims do not align with the supplied FDA-approved labeling excerpts for dextrose 50% injection; several statements (notably indications and dilution/alternatives) are not supported by the provided label text.
Category Scores
Accurate Statements
The physician selects the most appropriate fluid based on the patient's hydration status, electrolyte levels, and caloric requirements.
Not supported by the provided label excerpts (no matching text found).
Unsupported Statements
Dextrose 10% and sodium chloride 0.11% is an intravenous fluid used for hydration and to provide calories.
The supplied label excerpt is for Dextrose (50%) Injection indicated for insulin-induced hypoglycemia; no hydration/NaCl use or specific 10%/0.11% formulation is supported.
The combination of dextrose and sodium chloride aims to maintain electrolyte balance.
No supported indication/claim regarding a dextrose + sodium chloride combination maintaining electrolyte balance is present in the supplied label excerpts for Dextrose (50%).
Dextrose 10% provides a caloric source.
Supplied labeling excerpt for mechanism states dextrose provides carbohydrate calories, but it is for Dextrose Injection (50%); the claim about 'Dextrose 10%' specifically is not supported by the provided label text.
Sodium chloride helps maintain sodium and chloride levels in the body.
No sodium chloride content or sodium/chloride maintenance claim is supported in the provided label excerpts for dextrose (50%).
This intravenous solution is used to treat or prevent dehydration.
No supported indication for dehydration treatment/prevention exists in the provided label excerpts.
It is used when fluid loss is accompanied by a need for calories.
No supported indication for 'fluid loss' with need for calories exists in the provided label excerpts.
It can be used as a diluent for other injectable medications that are not incompatible.
No statement about use as a diluent for other injectable medications is present in the provided label excerpts.
The solution is administered intravenously through a needle or catheter inserted into a vein.
While the label excerpt states administer intravenously, it does not support the specific phrasing about needle/catheter insertion; only route (IV vs SC/IM) is explicitly supported.
Dosage and administration rates are determined by a physician.
The label provides recommended dosage and max infusion rate but does not explicitly state physician discretion in the provided excerpts.
Dosage and administration rates depend on the patient's age, weight, clinical condition, and electrolyte status.
The label excerpt includes pediatric guidance and monitoring, and gives a max rate (0.5 g/kg/hour), but does not explicitly state that administration rates depend on age/weight/clinical condition/electrolyte status in the provided text.
Potential risks of this intravenous therapy include infection at the injection site.
The provided label excerpts list administration site conditions such as blister, extravasation, erythema, pain, vein damage, thrombosis, and phlebitis; 'infection at the injection site' is not supported.
Alternative intravenous solutions containing only dextrose at different concentrations (e.g., D5W) may be used.
The supplied label excerpts do not mention D5W or alternative dextrose concentrations for this indication.
Alternative intravenous solutions include solutions with different electrolyte compositions (e.g., Lactated Ringer's solution, 0.9% sodium chloride).
The supplied label excerpts only mention considering an alternative commercially available dextrose product with a lower concentration for certain pediatric peripheral access circumstances; they do not support lactated Ringer's or 0.9% sodium chloride as alternatives.
The physician selects the most appropriate fluid based on the patient's hydration status, electrolyte levels, and caloric requirements.
No matching selection framework based on hydration status/caloric requirements is present in the provided label excerpts for Dextrose (50%).
Contradictions
Low
AI Statement
Dextrose 10% and sodium chloride 0.11% is an intravenous fluid used for hydration and to provide calories.
Label Reference
Indications and Usage (1): Dextrose (50%) Injection is indicated for insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older.
Low
AI Statement
This intravenous solution is used to treat or prevent dehydration.
Label Reference
Indications and Usage (1): No indication for dehydration treatment/prevention is provided in the supplied label excerpt.
Low
AI Statement
It can be used as a diluent for other injectable medications that are not incompatible.
Label Reference
The supplied label excerpts do not include any statement allowing use as a diluent; therefore it is not supported by label.
Important Omissions
Indication should be insulin-induced hypoglycemia (adults and pediatric patients 2 years of age and older), which is not stated in the AI claims provided.
Importance:
High
For Dextrose Injection (50%), administration instructions include obtaining a blood glucose level prior to administering (with emergency exception) and not administering subcutaneously/IM; the AI claims do not reflect these specific preparation/administration requirements.
Importance:
Moderate
Hyponatremia guidance in label includes 'avoid in patients with or at risk for hyponatremia' and monitoring specific parameters; the AI mentions risk but does not include the 'avoid' and monitoring specifics from the supplied text.
Importance:
Moderate
Contraindications (intracranial/intraspinal hemorrhage, severe dehydration, alcohol withdrawal, known hypersensitivity) are not addressed at all in the AI claims.
Importance:
High
Specific pediatric administration instruction: administer into a central vein and avoid peripheral vein in pediatric patients 2 to 11 years; consider alternative lower-concentration dextrose product if central access cannot be obtained. This is not included.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI claims include unsupported indications (hydration/dehydration treatment) and an alternative formulation/usage as diluent that are not supported by the supplied Dextrose (50%) label excerpts, and omit major contraindications and key administration constraints/monitoring details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims are largely about a different formulation (dextrose 10% + sodium chloride 0.11%) and different indications (hydration/dehydration), whereas the supplied FDA label excerpt is for Dextrose (50%) injection indicated for insulin-induced hypoglycemia with specific administration/contraindication/monitoring requirements not reflected.
Suggested Improvement
Rebase claims strictly on the supplied label excerpt for Dextrose (50%) Injection: state correct indication, remove hydration/dehydration and NaCl-combination claims, align administration with label requirements (IV only; slow infusion; avoid too rapid infusion; pediatric central-vein guidance), and include key contraindications and the label-specific hyponatremia and fluid overload monitoring/avoidance language.